Esperion VGM score still graded as F

[CB's Stockbroker]

All the talk about momentum the stock is still looked at by Wall Street with and F rating. It's in the bottom 40% of stock expectations . All the talk of going from generating 600k in sales in second quarter to 3.6 million is still pitiful. Were talking about a launch and blaming everything in Covid is just Ann Arbor looking for an excuse. When you look at companies that launched during the same time frame there light years ahead in sales and success. Look at Biohavens launch. They still conducted a launch meeting which wasn't the safest thing to do but their sales teams responded with good sales. Nothing like the Tic Tok and Call of Duty crowd of reps at Esperion sticking their chests out because they were a Scientific Hire. Fact of the matter is in pharma if you don't make an impact in a launch in two quarters the drug is a failure. That's how marketing looks at this.

 

[anonymous]

The latest article in Zacks Investment Research was bought and paid for by Esperion to try and drum up stock interest. How can a company with a grade F or a D in growth and momentum even warrant an article in the investment community. This is a smoke and mirrors outfit from the start.